Pfizer Inc., announced the results of a phase three study on Monday demonstrating that Prevnar 13(R) showed immunogenicity and established a safety profile in children ages five through 17.
Prevnar 13(R) - Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) - is a pneumococcal disease vaccine currently approved in children ages six weeks through five years old. It is also approved for adults 50 years of age and older.
The results of the study were presented on Monday during the 8th International Symposium on Pneumococci and Pneumococcal Diseases in Iguacu Falls, Brazil. Pfizer will seek regulatory submissions to expand the label of Prevnar 13 in the European Union, the United States and other countries worldwide.
"As a global leader in pneumococcal disease prevention, we are excited about the potential to further define the clinical utility of Prevnar 13 with the aim of seeking to broaden prevention efforts to additional age groups," Emilio Emini, the chief scientific officer of the vaccine research department at Pfizer, said. "While pneumococcal disease most often strikes younger children, older children and adolescents who have certain medical conditions are also at heightened risk for contracting the disease."
Pneumococcal disease is a group of illnesses caused by the bacterium Streptococcus pneumoniae. The illnesses can affect people of all ages and include sinusitis, bacteremia and meningitis.